Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare... see more

NDAQ:INM - Post Discussion

InMed Pharmaceuticals Inc > InMed Earnings 10 Feb 2022
View:
Post by Bullknit101 on Feb 09, 2022 5:41pm

InMed Earnings 10 Feb 2022

Looking for first ever revenue numbers. Prolly around $200-$300k for the quarter. https://www.nasdaq.com/market-activity/stocks/inm/earnings?random=6204106e960ed
Comment by Bullknit101 on Feb 10, 2022 12:43pm
According to the NASDAQ website, the 10 Feb release date was based on an algorithm. Earnings released is on actually on 15 Feb 2022. https://financialpost.com/globe-newswire/inmed-pharmaceuticals-to-report-second-quarter-fiscal-2022-financial-results-and-business-update-on-february-15-2022
Comment by Stevemin on Feb 10, 2022 5:31pm
Inmed IR has all but said not to expect any insight on the retail numbers. I have a sneaky suspicion that they dont give any hard numbers at all and blame it on the fact that they have been too busy closing the deal.  Remember, Adams is never transparent and he offers nothing to his shareholders and his whole time with Inmed he has been good at 3 things: 1 - Lacking transparency to the point ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities